Trial Profile
A Prospective, Single-Arm, Open-Label, Non-Randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9-11 Year-Old Girls and Boys
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 07 Feb 2024 Planned End Date changed from 6 Feb 2024 to 6 Feb 2025.
- 05 Aug 2023 Planned End Date changed from 31 Dec 2022 to 6 Feb 2024.
- 27 Jul 2017 Planned primary completion date changed from 31 May 2020 to 29 Feb 2020.